Novartis Overview
Novartis AG focuses its business on three divisions: pharmaceuticals, eye care (Alcon), and generics (Sandoz). These three divisions are supported by the research organization, the Novartis Institutes for BioMedical Research, and a centralized services group, Novartis Business Services, to facilitate collaboration across the divisions and drive efficiency and productivity gains. In Israel, in addition to the marketing department, Novartis has a division engaged in medical research and development of new drugs and a wide range of clinical research activities. In 2009, Alcon, a subsidiary of Novartis, acquired Optonol, a company that develops devices for ophthalmologic applications and glaucoma surgery. Since its acquisition, Optonol operates as a subsidiary of the company. Novartis also operates in Israel a Cyber Security research center. Novartis is also present in Israel, through its innovation center BIOME.
Latest News
growth-positive
RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline
Roche has announced its acquisition of 89bio, a clinical-stage biopharmaceutical company, for $3.5 billion. This strategic move aims to enhance Roches portfolio in cardiovascular, renal, and metabolic diseases by adding 89bios promising phase III candidate, pegozafermin, to its pipeline. Pegozafermin is in late-stage development for treating metabolic dysfunction-associated steatohepatitis (MASH) in fibrotic and cirrhotic patients. The acquisition, approved by both companies boards, is expected to close in the fourth quarter of 2025. The deal includes a contingent value right (CVR) for 89bio stockholders, potentially increasing the total consideration by up to $1 billion if certain sales milestones are met. This acquisition is seen as a positive growth opportunity for Roche, aligning with its strategic focus on lucrative therapeutic areas.
Acquisition
growth-positive
[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
The article discusses a market research report by Custom Market Insights on the global Biologics and Biosimilars market. The report highlights the markets growth potential, with an expected increase from USD 478.83 billion in 2024 to USD 1,320.19 billion by 2034, at a CAGR of 10.42%. The growth is driven by the rising incidence of chronic diseases like cancer and diabetes, necessitating long-term treatments. The expiration of patents for major biologics has opened the market for biosimilars, offering cost-effective alternatives. The report also emphasizes advancements in biomanufacturing technologies that enhance production efficiency.
growth-positive
Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB
The Saudi Arabian Osteoporosis Drugs Market is projected to grow significantly, driven by an aging population, increasing osteoporosis rates, and favorable healthcare regulations. The market is expected to expand from $210.89 million in 2024 to $308.84 million by 2033, with a CAGR of 4.33% from 2025. While bisphosphonates remain popular due to cost-effectiveness, biologics are anticipated to grow rapidly. Government initiatives under Vision 2030 are enhancing local drug production and healthcare infrastructure, improving drug accessibility. However, challenges such as low adherence and rural access persist. Key players include Amgen, Eli Lilly, and Pfizer. The market is concentrated in urban areas, with rural regions facing limited access to experts and treatments.
growth-positive
Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA
The article discusses the addition of the Multiple Sclerosis - Global Clinical Trials Review, 2025 report to ResearchAndMarkets.coms offerings. This report provides a comprehensive overview of the global landscape of clinical trials for Multiple Sclerosis, including data by region, phase, and sponsor. It highlights top drugs and trial trends, aiding in strategic decision-making and competitive advantage. The report is generated using a proprietary database and includes data from over 80 clinical trial registries and other sources. It aims to assist in formulating business strategies, identifying key locations for trials, and understanding global market opportunities.
Product Stage
growth-positive
Buy These 5 Low-Leverage Stocks Amid Impressive Retail Sales Data
The article discusses the positive performance of U.S. stock indices on July 17, 2025, driven by growth factors such as improved retail sales and decreased unemployment claims. Notably, Netflixs better-than-expected earnings results contributed to investor confidence and Wall Streets performance. The article advises investors to consider low-leverage stocks like Novartis, ResMed Inc., Wabtec, Elbit Systems, and Ingredion Inc. to mitigate risks associated with market volatility. It explains the concept of leverage and its implications for financial risk, emphasizing the importance of selecting companies with lower debt-to-equity ratios for safer investments.
Team Members
1
Employees: 51-200
Web & Social Links
| Website | www.novartis.com |
Locations
Totseret ha-Arets Street 6, Tel Aviv-Yafo, Israel
Neve Ilan, Israel
Basel, Switzerland
Photos & Videos
No files yet
Novartis Business
Business models
—
Product stage
—
Employees
51-200
Sector
—Target Customer
—Core Technology
—Tags (5)
cyber-securityophthalmologyglaucomasurgeryinnovation-centerNovartis Financials
—
Total funding
—
Capital raised
—
Last funding
—
Funding stage
—
Total rounds
—
Investors
Public Offering / Exit
POEvent
May 2020
Undisclosed
POEvent
Oct 2018
Undisclosed
Novartis Lifecycle
All Events
POEvent
May 2020
Undisclosed
POEvent
Oct 2018
Undisclosed
Novartis News
11 articles
growth-positive
RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline
Roche has announced its acquisition of 89bio, a clinical-stage biopharmaceutical company, for $3.5 billion. This strategic move aims to enhance Roches portfolio in cardiovascular, renal, and metabolic diseases by adding 89bios promising phase III candidate, pegozafermin, to its pipeline. Pegozafermin is in late-stage development for treating metabolic dysfunction-associated steatohepatitis (MASH) in fibrotic and cirrhotic patients. The acquisition, approved by both companies boards, is expected to close in the fourth quarter of 2025. The deal includes a contingent value right (CVR) for 89bio stockholders, potentially increasing the total consideration by up to $1 billion if certain sales milestones are met. This acquisition is seen as a positive growth opportunity for Roche, aligning with its strategic focus on lucrative therapeutic areas.
Acquisition
growth-positive
[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
The article discusses a market research report by Custom Market Insights on the global Biologics and Biosimilars market. The report highlights the markets growth potential, with an expected increase from USD 478.83 billion in 2024 to USD 1,320.19 billion by 2034, at a CAGR of 10.42%. The growth is driven by the rising incidence of chronic diseases like cancer and diabetes, necessitating long-term treatments. The expiration of patents for major biologics has opened the market for biosimilars, offering cost-effective alternatives. The report also emphasizes advancements in biomanufacturing technologies that enhance production efficiency.
growth-positive
Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB
The Saudi Arabian Osteoporosis Drugs Market is projected to grow significantly, driven by an aging population, increasing osteoporosis rates, and favorable healthcare regulations. The market is expected to expand from $210.89 million in 2024 to $308.84 million by 2033, with a CAGR of 4.33% from 2025. While bisphosphonates remain popular due to cost-effectiveness, biologics are anticipated to grow rapidly. Government initiatives under Vision 2030 are enhancing local drug production and healthcare infrastructure, improving drug accessibility. However, challenges such as low adherence and rural access persist. Key players include Amgen, Eli Lilly, and Pfizer. The market is concentrated in urban areas, with rural regions facing limited access to experts and treatments.
growth-positive
Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA
The article discusses the addition of the Multiple Sclerosis - Global Clinical Trials Review, 2025 report to ResearchAndMarkets.coms offerings. This report provides a comprehensive overview of the global landscape of clinical trials for Multiple Sclerosis, including data by region, phase, and sponsor. It highlights top drugs and trial trends, aiding in strategic decision-making and competitive advantage. The report is generated using a proprietary database and includes data from over 80 clinical trial registries and other sources. It aims to assist in formulating business strategies, identifying key locations for trials, and understanding global market opportunities.
Product Stage
growth-positive
Buy These 5 Low-Leverage Stocks Amid Impressive Retail Sales Data
The article discusses the positive performance of U.S. stock indices on July 17, 2025, driven by growth factors such as improved retail sales and decreased unemployment claims. Notably, Netflixs better-than-expected earnings results contributed to investor confidence and Wall Streets performance. The article advises investors to consider low-leverage stocks like Novartis, ResMed Inc., Wabtec, Elbit Systems, and Ingredion Inc. to mitigate risks associated with market volatility. It explains the concept of leverage and its implications for financial risk, emphasizing the importance of selecting companies with lower debt-to-equity ratios for safer investments.
growth-positive
Biotech Alert: Searches spiking for these stocks today
Chemomab Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases. Their lead product, nebokitug, is a monoclonal antibody targeting the soluble protein CCL24, which plays a role in fibrosis and inflammation. Nebokitug has shown promise in clinical trials, demonstrating a favorable safety profile and potential to treat severe fibro-inflammatory diseases. The company is preparing for a Phase 3 trial for primary sclerosing cholangitis (PSC), following positive Phase 2 results. Nebokitug has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC treatment. This article highlights the growth potential of Chemomab Therapeutics, as well as other biotech companies experiencing increased interest.
Product StageFDA approved/pending approval
growth-positive
Novartis Invests $10 Million in Anti-Cancer Company Ayala Pharmaceuticals
Pharma multinational Novartis International AG has made a $10 million equity investment in Ayala Pharmaceuticals Inc., a clinical-stage company developing targeted therapies for genetically-defined cancers. The investment is part of a licensing option agreement signed between the two companies. Novartis will evaluate one of Ayalas drug candidates for the treatment of multiple myeloma. Ayala will retain licensing rights for all other indications of the drug.
Investment
growth-positive
Ayala signs licensing deal with Novartis for blood cancer drug
Ayala Pharmaceuticals has entered into an option to license agreement with Novartis for its investigational agent AL102 in multiple myeloma. Ayala will receive a $10 million equity investment from Novartis and is eligible for milestone payments. Novartis will conduct studies to evaluate AL102 in combination with its B-cell maturation antigen (BCMA) therapies. Ayala raised $17 million in a Series A financing round earlier this year. AL102 is an oral small-molecule that inhibits gamma secretase and is being investigated as a potential treatment for multiple myeloma.
InvestmentPartners
growth-positive
Novartis to invest in $60m Gamida Cell Nasdaq IPO
Gamida Cell, an Israeli stem cell cancer therapy developer, has filed a revised public registration statement with the US Securities and Exchange Commission (SEC) to raise $50-60 million on Nasdaq at a company valuation of $275 million. The companys shareholders, including Novartis, will invest $30 million in the offering. Gamida Cell is currently enrolling patients in a Phase III clinical trial for its most advanced product candidate, NiCord, which is a NAM-expanded cord blood cell therapy. The company has raised over $100 million to date, including $40 million in June 2017.
Public TradingInvestment
growth-positive
Novartis seeks new Israeli technologies
Novartis AG has increased its interest in Israel by investing $35 million in Gamida Cell and signing a deal with BiolineRX Ltd. Novartis recognizes the technology in Israel and believes that BioLineRx is suitable for developing these technologies. The person directing Novartiss general strategy is David Epstein, who has served as Novartis Pharmaceuticals Division Head since 2010. Epsteins appointment indicates the companys growing focus on cancer treatment. Novartis has also announced a partnership with Google for digital healthcare. The company is looking to strengthen its ties with young start-ups and make targeted acquisitions, primarily through BioLineRx. Novartis is focused on developing cell therapy and gene therapy technologies and has a promising product pipeline.
InvestmentPartners
growth-positive
Optonol: Reaping $180m from a device the size of a grain of rice
Optonol, a company that develops microscopic drainage shunts for the treatment of glaucoma, will be sold to Alcon in a deal worth $200 million. Optonols shareholders will receive additional payments based on sales milestones. The sale is expected to benefit Pitango venture capital fund the most, estimated to receive $60 million. Israel HealthCare Ventures also owns a 13% stake in the company. Optonols product line, including the Ex-PRESS, helps reduce intraocular pressure in glaucoma patients. The company was founded in 1996 as a spin-off of Medinol and currently has 20 to 30 employees. Alcon, a U.S.-based medical giant, manufactures devices for ocular surgery and eye treatment products.
Acquisition
Novartis Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 180 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
Novartis Internal
Recent Updates
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2024-10-08 17:31:30.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2025-02-06 12:34:43.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-12-05 14:16:43.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2024-10-08 17:31:30.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-08-07 05:49:40.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-08-07 04:52:55.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-08-07 04:52:55.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-12-05 15:05:16.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-07-28 14:44:46.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-07-28 14:44:46.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-07-28 14:51:43.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-07-28 14:04:30.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-07-28 14:43:06.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-07-28 14:44:57.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-07-28 14:44:19.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-07-28 14:25:58.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-07-28 14:16:01.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-07-28 14:17:55.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-07-28 14:17:55.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-07-28 14:47:33.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-07-28 13:21:08.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-07-28 13:21:08.000000
Maor Perlov
· maorperlov@gmail.com · Manual · 2022-07-28 14:52:06.000000
Rom Lotan
· rom.lotan@gmail.com · Manual · 2018-12-24 22:09:31.000000
Rom Lotan
· rom.lotan@gmail.com · Manual · 2018-12-24 22:09:31.000000
Rom Lotan
· rom.lotan@gmail.com · Manual · 2018-12-24 22:09:31.000000
Rom Lotan
· rom.lotan@gmail.com · Manual · 2018-12-24 22:09:31.000000
Rom Lotan
· rom.lotan@gmail.com · Manual · 2018-12-24 22:09:33.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2019-01-17 10:13:53.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2019-01-17 10:14:52.000000
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 71/100 |
| Missing | product stage, sector, business model, video or image, funding rounds, markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Crunchbase | novartis |
| Phone | +97239201111 |
| Creator | Yamila Silbert |
| Creator email | yamila.urwicz@gmail.com |
| Last updater | Maor Perlov |
| Updater email | maorperlov@gmail.com |
| Last update | 2022-07-28T00:00:00.000Z |
| Created | 2016-05-15T00:00:00.000Z |
| Status detail | Public on SIX on Apr, 1995; |